Navigation Links
Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
Date:4/17/2008

WOODCLIFF LAKE, N.J., April 17 /PRNewswire/ -- Eisai Corporation of North America today announces the immediate appointment of Robert Laverty as Vice President of U.S. Corporate Communications. In this newly created position, Mr. Laverty will be responsible for overseeing and coordinating all of Eisai's corporate communications strategies and activities in the United States.

Mr. Laverty brings to Eisai more than 22 years of global corporate, product, policy and research and development communications experience in the pharmaceutical industry. Most recently, he served as Vice President, Global Communications, Malaria Initiatives for Novartis AG, where he oversaw all global communications supporting the company's malaria initiative in the developing world. In addition, Mr. Laverty has held several other executive titles at Novartis Pharmaceuticals Corp, including Vice President, External Communication and Vice President, Global Pharma Media Relations.

Earlier in his career, Mr. Laverty held a number of progressively responsible positions in corporate policy, corporate affairs, and product public affairs at Bristol-Myers Squibb Company. He holds a Bachelor of Science degree in pharmacy from St. John's University, Jamaica, New York.

"Mr. Laverty is a welcome addition to our company and will be instrumental in strengthening Eisai's visibility and presence in the U.S. as a top-20 pharmaceutical company," said Lonnel Coats, President & COO, Eisai Corporation of North America. "With his more than two decades of senior communications expertise in the global pharmaceutical industry, Mr. Laverty's contributions to our company will be invaluable, as we continue to fulfill our human health care (hhc) mission to satisfy unmet medical needs and increase benefits to patients and their families."

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, Inc., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery. For more information about Eisai, please visit http://www.eisai.com.


'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DARA Announces Surgi-Vision Agreement with Boston Scientific Corporation
2. Torchmark Corporation Reports First Quarter 2008 Results
3. Digirad Corporation to Release First Quarter Financial Results on April 24, 2008
4. Otter Tail Corporation Holds 2008 Annual Meeting: Shareholders Elect Directors; Board Declares Quarterly Dividend
5. Microflex Corporation Launches New Website
6. Linkwell Corporation Selected to Train and License all Disinfectant and Pest Control Professionals in China and for the Beijing Olympics
7. Zipfizz(R) Announces Distribution Deal With the Odom Corporation
8. Alsius Corporation Awarded Three-Year Agreement With MedAssets Supply Chain Systems
9. BioElectronics Corporations New Commercial Airing Nationally Advertising Initiative Will Reach 15,000,000 Homes Nationwide
10. Linkwell Corporation Year-End 2007 Earnings Release and Conference Call Notice
11. Albemarle Corporations First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 8:00am ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... Bay, Jamaica (PRWEB) , ... April 30, 2016 ... ... University, and Duane Boise, President and CEO of EMED, today signed a multifaceted ... Jamaica. , EMED and the Northern Caribbean University Department of Natural and Applied ...
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. ... gold in Rio. Under the care of Maximized Living doctors at the London ... unprecedented showing, Maximized Living is sending the largest contingent of elite chiropractors to Rio ...
(Date:4/29/2016)... ... 2016 , ... In an article published April 16th on the ... and lip injections, which she underwent in order to feel more at home at ... Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is ... even security. Most importantly, employees are the single most important asset in creating ... so unhappy? , Just under half of American workers are emotionally checked out ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 Treato ... on healthcare, announced today that it has been named ... Cool Vendor in Life Sciences, 2016, Stephen ...  The report focuses on life-science- oriented analytics, algorithms and ... patients and doctors, confirm medication ingestion, and analyze unstructured ...
(Date:4/28/2016)... , April 28, 2016 Oramed ... a clinical-stage pharmaceutical company focused on the development of oral ... in the upcoming PIONEERS 2016 conference, presented by Joseph ... 2016 in New York . Nadav ... at the conference. Presentation Details:   ...
(Date:4/28/2016)... -- TapImmune,Inc. (TPIV), a clinical-stage immune-oncology ... immunotherapeutics and vaccines for the treatment of cancer & metastatic ... Annual Growth Capital Expo to be held on May ... Palace in Las Vegas, Nevada.  The Company presentation will ... by Dr. John N. Bonfiglio a TapImmune ...
Breaking Medicine Technology: